Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing reports an increase in ordinary share interests for several executives following the re-investment of dividends paid on October 6, 2011. The shares were purchased at a price of 1,396.06 pence per share on October 11, 2011. No other material changes to the company's financial position or operations are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in ordinary share holdings by directors and connected persons via dividend re-investment.
- Transaction Date: October 11, 2011.
- Share Price: 1,396.06 pence per share.
- Dividend Date: October 6, 2011.
- Participants: Includes Dr M M Slaoui, Mr S M Bicknell, Mr J M Clarke, Mr M Dunoyer, Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Mr J R Stéphenne, Ms C Thomas, Mr P C Thomson, and Dr P J T Vallance.
- Notification Date: The company was advised of these transactions on October 12, 2011.